Disclaimer

The information contained in this website is for general information purposes only. The information is provided by Gravity Capital and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

  • Suite 4232, Weelock Square, 1717 West Nanjing RD, Shanghai, China
  • 86-21-80286071
  • info@gravitycapital.com
  • Disclaimer

    The information contained in this website is for general information purposes only. The information is provided by Gravity Capital and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

    In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

  • address:
    Suite 4232, Weelock Square, 1717 West Nanjing RD, Shanghai, China
  • tel:
    86-21-80286071
  • email:
    info@gravitycapital.com
  • scroll
    About Us

    Gravity Capital is an international private equity group focusing on the fast growing healthcare industry in the Greater China region. Founded in 2006, Gravity Capital carry out investment activities in healthcare, medical and biotechnology sectors in the region through headquarter in Shanghai and two branches in Taipei and Hong Kong. Gravity Capital engages global investment specialists, local industry experts and entrepreneurs with more than 30 years of experience in studying and investing in healthcare industry and with established rich industry resources and broad connections. In China mainland, Gravity Capital is partnering with China's top university to venture invest predominantly in domestic early-stage healthcare businesses with innovative products and technology barriers. 

    Fudan-Med&Gravity

    Our Portfolio
    • Leading high-end chain dental clinic in China

      2017 Zero2IPO: Top 50 most investment value company in China

      2018 VCbeat, Legend Capital, Baidu: Top 100 future healthcare company

      2019 VCbeat: Top 100 future healthcare company

      2019 Chinese Venture: Top 50 most investment value company in China


    • Renowned digital medical imaging equipment R&D company in China

      2017 China venture: Top 10 investment cases in Chinese medical devices sector

      2018 Zero2IPO: Top 50 most investment value companies in China

      2019 VB100: Top 100 medical device companies in China


    • Leading cancer diagnostic technology R&D company in China

      2017:Top 100 most growing companies in Jiangsu Province

      2018:”Zhong Nan Shan” Second award for technology innovation

      2018:Second award for private technological development contribution


    • Tumor serum and protein marker R&D company in China

      One among only few developers in China that are capable of discovering, developing and commercializing novel protein markers for cancer diagnostics.

    • The only R&D and manufacturer of high-capacity CT tube in China

      2018 China technology innovation association: technology innovation contribution

      2018 India creation association: Gold award

      2018 International invention exhibition: invention startup award

    • Automated PD manchine and CKD management service provider

      Emedtech Group is now running the world’s largest online PD treatment platform, covering 6000 patients from 106 hospitals in 18 provinces in China.

    • The world's leading bioartificial liver system

      2018 Hurun: Top 50 most investment value companies in Hubei Province

      2019 Guanggoo:Top 20 growing high-tech companies

      2019 Maker in China: Second award for SME Innovation and Entrepreneurship Competition in Hubei Province


    • Mid-to-high-end chain skin allergy clinics in China
    • World leading solid tumor CAR-T technology R&D company

      New generation CAR-T technology that is promising in effective and safe treatment of solid tumor by preliminary clinical study.

    • R&D company for leptin biosimilar drugs

      AmeriShen BioMedicine aims to develop 3 indications of Leptin and one is close to IND submission.

    • Semiconductor NGS equipment R&D company in China

      Develop semi-conduct NGS equipment featured as low running cost and meet daily testing requirement by hospitals.

    • Commercial health insurance data service platform in China

      Develop internet and cloud technologies that facilitate data transfer between insurance company and hospital to improve the efficiency of insurance service.

    • Development of novel fully humanized antibody-drugs

      Dedicated to the development of novel antibody-drugs for cancer, autoimmune and metabolic disease

    • Renowned infant healthcare management platform in China

      2019 Yiou:Chinese healthcare industry best non-public innovative company award

      2019 Forbes China: Dr. Cui as Top 10 KOL in maternal and infant sector

      2019 VCbeat: Top 100 future healthcare company


    • International mid-to-high-end private rehabilitation hospital
    • The largest online healthcare service platform in China

      2019 Frost & Sullivan: New Economy Award in China

      2018 Pitchbook: most valuable private tech companies in the world

      2017 CB insights: Top150 Global digital health unicorn startups

    • Boutique chain eye clinic group

      Chain eye clinics that provide optometry, eye care and medical service to middle class family in China

    • Renowned brand for anti-aging and private healthcare management in China

      Provides anti-aging and specialist medical service to middle-class and high net-worth people

    • Leading high-end chain dental clinic in China

      2017 Zero2IPO: Top 50 most investment value company in China

      2018 VCbeat, Legend Capital, Baidu: Top 100 future healthcare company

      2019 VCbeat: Top 100 future healthcare company

      2019 Chinese Venture: Top 50 most investment value company in China


    • Renowned digital medical imaging equipment R&D company in China

      2017 China venture: Top 10 investment cases in Chinese medical devices sector

      2018 Zero2IPO: Top 50 most investment value companies in China

      2019 VB100: Top 100 medical device companies in China


    • Leading cancer diagnostic technology R&D company in China

      2017:Top 100 most growing companies in Jiangsu Province

      2018:”Zhong Nan Shan” Second award for technology innovation

      2018:Second award for private technological development contribution


    • Tumor serum and protein marker R&D company in China

      One among only few developers in China that are capable of discovering, developing and commercializing novel protein markers for cancer diagnostics.

    • The only R&D and manufacturer of high-capacity CT tube in China

      2018 China technology innovation association: technology innovation contribution

      2018 India creation association: Gold award

      2018 International invention exhibition: invention startup award

    • Automated PD manchine and CKD management service provider

      Emedtech Group is now running the world’s largest online PD treatment platform, covering 6000 patients from 106 hospitals in 18 provinces in China.

    • The world's leading bioartificial liver system

      2018 Hurun: Top 50 most investment value companies in Hubei Province

      2019 Guanggoo:Top 20 growing high-tech companies

      2019 Maker in China: Second award for SME Innovation and Entrepreneurship Competition in Hubei Province


    • Mid-to-high-end chain skin allergy clinics in China
    • World leading solid tumor CAR-T technology R&D company

      New generation CAR-T technology that is promising in effective and safe treatment of solid tumor by preliminary clinical study.

    • R&D company for leptin biosimilar drugs

      AmeriShen BioMedicine aims to develop 3 indications of Leptin and one is close to IND submission.

    • Semiconductor NGS equipment R&D company in China

      Develop semi-conduct NGS equipment featured as low running cost and meet daily testing requirement by hospitals.

    • Commercial health insurance data service platform in China

      Develop internet and cloud technologies that facilitate data transfer between insurance company and hospital to improve the efficiency of insurance service.

    • Development of novel fully humanized antibody-drugs

      Dedicated to the development of novel antibody-drugs for cancer, autoimmune and metabolic disease

    • Renowned infant healthcare management platform in China

      2019 Yiou:Chinese healthcare industry best non-public innovative company award

      2019 Forbes China: Dr. Cui as Top 10 KOL in maternal and infant sector

      2019 VCbeat: Top 100 future healthcare company


    • International mid-to-high-end private rehabilitation hospital
    • The largest online healthcare service platform in China

      2019 Frost & Sullivan: New Economy Award in China

      2018 Pitchbook: most valuable private tech companies in the world

      2017 CB insights: Top150 Global digital health unicorn startups

    • Boutique chain eye clinic group

      Chain eye clinics that provide optometry, eye care and medical service to middle class family in China

    • Renowned brand for anti-aging and private healthcare management in China

      Provides anti-aging and specialist medical service to middle-class and high net-worth people

    • Leading high-end chain dental clinic in China

      2017 Zero2IPO: Top 50 most investment value company in China

      2018 VCbeat, Legend Capital, Baidu: Top 100 future healthcare company

      2019 VCbeat: Top 100 future healthcare company

      2019 Chinese Venture: Top 50 most investment value company in China


    • Renowned digital medical imaging equipment R&D company in China

      2017 China venture: Top 10 investment cases in Chinese medical devices sector

      2018 Zero2IPO: Top 50 most investment value companies in China

      2019 VB100: Top 100 medical device companies in China


    • Leading cancer diagnostic technology R&D company in China

      2017:Top 100 most growing companies in Jiangsu Province

      2018:”Zhong Nan Shan” Second award for technology innovation

      2018:Second award for private technological development contribution


    • Tumor serum and protein marker R&D company in China

      One among only few developers in China that are capable of discovering, developing and commercializing novel protein markers for cancer diagnostics.

    • The only R&D and manufacturer of high-capacity CT tube in China

      2018 China technology innovation association: technology innovation contribution

      2018 India creation association: Gold award

      2018 International invention exhibition: invention startup award

    • Automated PD manchine and CKD management service provider

      Emedtech Group is now running the world’s largest online PD treatment platform, covering 6000 patients from 106 hospitals in 18 provinces in China.

    • The world's leading bioartificial liver system

      2018 Hurun: Top 50 most investment value companies in Hubei Province

      2019 Guanggoo:Top 20 growing high-tech companies

      2019 Maker in China: Second award for SME Innovation and Entrepreneurship Competition in Hubei Province


    • Mid-to-high-end chain skin allergy clinics in China
    • World leading solid tumor CAR-T technology R&D company

      New generation CAR-T technology that is promising in effective and safe treatment of solid tumor by preliminary clinical study.

    • R&D company for leptin biosimilar drugs

      AmeriShen BioMedicine aims to develop 3 indications of Leptin and one is close to IND submission.

    • Semiconductor NGS equipment R&D company in China

      Develop semi-conduct NGS equipment featured as low running cost and meet daily testing requirement by hospitals.

    • Commercial health insurance data service platform in China

      Develop internet and cloud technologies that facilitate data transfer between insurance company and hospital to improve the efficiency of insurance service.

    • Development of novel fully humanized antibody-drugs

      Dedicated to the development of novel antibody-drugs for cancer, autoimmune and metabolic disease

    • Renowned infant healthcare management platform in China

      2019 Yiou:Chinese healthcare industry best non-public innovative company award

      2019 Forbes China: Dr. Cui as Top 10 KOL in maternal and infant sector

      2019 VCbeat: Top 100 future healthcare company


    • International mid-to-high-end private rehabilitation hospital
    • The largest online healthcare service platform in China

      2019 Frost & Sullivan: New Economy Award in China

      2018 Pitchbook: most valuable private tech companies in the world

      2017 CB insights: Top150 Global digital health unicorn startups

    • Boutique chain eye clinic group

      Chain eye clinics that provide optometry, eye care and medical service to middle class family in China

    • Renowned brand for anti-aging and private healthcare management in China

      Provides anti-aging and specialist medical service to middle-class and high net-worth people

    Our Strategies

    Focuse on healthcare in Greater China

    China spend RMB 6.5 trillion yearly on healthcare which grow rapidly. The rise of health awareness, favorable policies and attraction of talents have brought huge unmet market demand and innovative startups. Our team have been studying and dealing with this market for more than 20 years.

    Novel tech and product oriented

    We maintain long-term connections with various high-tech facilities in Greater China region, including colleges, healthcare facilities, R&D institutions and technology parks as good source of novel-tech companies. From those we explore target with good clinical application and high market potential.

    Target high growth healthcare sectors

    We target high growth sectors through solid forward-looking study and in these sectors locate companies that are entering into stage of rapid growth. We adopt a projected IRR approach on making investment decisions to minimize our risk.

    Cooperation with entrepreneurs

    Our team members are rich in expertise and experience in healthcare, capital market and business operation. We work with entrepreneurs by leveraging our knowledge and industry resources to achieve goal of the company and consequently to optimize investment return.

    Investment Sectors
    • Life science and biotech
      China has rich R&D talents and comprehensive infrastructure in life science and biotech sectors, which contribute to rapid R&D progress in genomics, transcriptomics, proteomics, metabolomics, cell mapping research, etc.
    • Medical device and consumables
      Medical device and consumable industry in China is used to be characterized by low market concentration with 20000 small-to-medium manufacturers around the nation. Recent trend of continuous upgrade and integration of the industry will offer vast opportunities for small innovative companies.
    • Healthcare service
      Public hospitals are the dominant healthcare facilities in China to provide basic and universal medical coverage. But a plenty of investment opportunities raise as the surge of private healthcare facilities in recent years to meet the great demand for higher quality healthcare service as a result of rapid growth of Chinese income and living standard.
    • Healthcare IT
      China is low in proportion of medical workers to its population and its healthcare development is highly diversified across the country. Healthcare IT, which provides solutions in field of hospital and regional Healthcare IT, digital medical imaging, online healthcare, AI and big data, is one of the key to relieve the gap by improving efficiency and skills of medical staffs and facilitating cooperation and sharing among hospitals in different areas to increase overall medical capability.
    Target Investment Stage
    Contact Us
    Loading...
    • Telephone:

      86-21-80286071
    • Email:

      info@gravitycapital.com
    • Address:

      Suite 4232, Weelock Square, 1717 West Nanjing RD, Shanghai, China